Related references
Note: Only part of the references are listed.From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes
A. S. Kesselheim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views
G. Tafuri et al.
ANNALS OF ONCOLOGY (2014)
Accelerated Access to Innovative Medicines for Patients in Need
L. G. Baird et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
FDA's post-approval studies continue to suffer delays and setbacks
Cassandra Willyard
NATURE MEDICINE (2014)
Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration The Class of 2008
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2014)
A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors
Rashmi R. Shah et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
Michael B. Shea et al.
CLINICAL CANCER RESEARCH (2013)
A Forensic Analysis of Drug Targets From 2000 Through 2012
B. Munos
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The Food and Drug Administration Amendments Act and Postmarketing Commitments
Kevin Fain et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
The risks of risk aversion in drug regulation
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
H-G Eichler et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Factors influencing non-approval of new drugs in Europe
Michelle Putzeist et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Regulatory Review of Novel Therapeutics - Comparison of Three Regulatory Agencies
Nicholas S. Downing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Additional safety risk to exceptionally approved drugs in Europe?
Arna H. Arnardottir et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
Samantha A. Roberts et al.
HEALTH AFFAIRS (2011)
Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice
Francesco Trotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
Kevin V. Blake et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe
W. P. C. Boon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?
Elizabeth A. Richey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Share Paper
